Barberry for Antimicrobial Action

Table of Contents

1. Historical Background — Persian and European Use
2. Berberine's Four-Pronged Antimicrobial Mechanism
3. The Antimicrobial Spectrum of Barberry / Berberine
4. The 1985 Burma and 1987 Bangladesh Diarrhoea Trials
5. Barberry vs Goldenseal — the NorA Efflux Pump Question
6. Giardiasis and Other Protozoal Infection
7. Traveler's Diarrhea and Acute Gastroenteritis
8. Urinary Tract Infections
9. Skin, Eye, and Mucosal Infection
10. Effect on the Commensal Gut Microbiome
11. Dosing and Practical Forms (Decoction, Tincture, Capsule)
12. Cautions and Drug Interactions
13. Key Research Papers
14. Connections
15. Featured Videos

Historical Background — Persian and European Use

The medicinal use of barberry is at least 3,000 years old. Cuneiform tablets from the library of Ashurbanipal (7th century BCE) describe barberry preparations used to "purify the blood" in fever, a description consistent with modern understanding of antimicrobial action against bloodstream and enteric infection. Persian medicine integrated barberry as zereshk root for hepatitis, jaundice, and dysentery, and the dried red berries (also called zereshk) became and remain a staple of Persian cuisine, classically scattered over saffron rice in zereshk polo. The medicinal use of the berry is much milder than the root because berberine is concentrated in the inner bark and root tissue, not the fruit.

Greek and Roman herbalists including Dioscorides (1st century CE) described barberry-like preparations for diarrhea and "rotting" mucosal conditions. European medieval and early modern herbalists used barberry root bark in tinctures for jaundice, malaria, and dysentery. The herb was sufficiently important that an English statute in 1660 required eradication of barberry bushes within a certain distance of grain fields because they were correctly identified as the alternate host of the wheat rust fungus (Puccinia graminis) — an early example of plant-pathology epidemiology that has nothing to do with herbal medicine but illustrates the historical ubiquity of the plant.

Native American use of the closely related Berberis aquifolium (Oregon grape) and Berberis canadensis overlapped considerably with Eclectic and Physiomedical use in the 19th century United States. The Eclectic Materia Medica of John King and Harvey Wickes Felter described barberry root as a "stomachic, tonic, and laxative" with particular value in "jaundice, hepatic torpor, indigestion, and chronic dyspepsia" — indications that align well with modern understanding of berberine's cholagogue, AMP-activated protein kinase (AMPK), and antimicrobial actions.

The isolation of berberine itself dates to 1837 (independently by Buchner & Herberger in Germany and Hayman in England, working from Xanthoxylum clava-herculis and other source plants). The compound was named for the Berberis genus where it had first been characterized chemically. The structural assignment as a quaternary ammonium isoquinoline alkaloid was completed in the early 20th century. The mechanism of antimicrobial action was first explored in mid-20th-century pharmacology and progressively elaborated through the 1980s clinical trials and subsequent molecular biology work.

Back to Table of Contents

Berberine's Four-Pronged Antimicrobial Mechanism

One of the reasons berberine has retained clinical interest while many other plant antimicrobials have faded is that it works through multiple simultaneous mechanisms, none of which are vulnerable to single-point resistance mutations. The four major mechanisms:

1. DNA intercalation and topoisomerase inhibition — the planar tetracyclic aromatic structure of berberine slides between the stacked base pairs of double-stranded DNA, distorting the helix and preventing the action of bacterial topoisomerases. The intercalation is preferential for GC-rich regions. The functional effect is inhibition of bacterial DNA replication and transcription — the same general target class as the fluoroquinolone antibiotics, though by a different specific mechanism.
2. FtsZ inhibition (blocks cell division) — FtsZ is the bacterial cell-division protein that polymerizes at the future division site (the Z-ring) and recruits the cell-wall synthesis machinery needed to construct the dividing septum. Berberine binds FtsZ and prevents Z-ring assembly, blocking cell division. The bacteria continue to grow as long filaments without dividing, eventually losing membrane integrity. FtsZ has no eukaryotic homolog (animal cell division uses actin/myosin), so the mechanism is selective for bacteria.
3. Membrane disruption at higher concentrations — the quaternary nitrogen of berberine carries a permanent positive charge, allowing it to associate with negatively charged bacterial membrane phospholipids (cardiolipin and phosphatidylglycerol in particular, both more abundant in bacterial than mammalian membranes). At concentrations above approximately 50-100 µg/mL, this causes membrane depolarization and increased permeability.
4. Inhibition of microbial adhesion — berberine downregulates expression and assembly of bacterial adhesins including type I fimbriae and the FimH adhesin (which mediates E. coli adhesion to bladder uroepithelium), reducing the ability of pathogens to colonize mucosal surfaces in the first place. This is particularly relevant in urinary tract infection prevention.

The combination is synergistic: a bacterium that mutated to evade DNA intercalation would still face FtsZ inhibition and adhesion blockade. The closest pharmaceutical analog is the multi-target antibiotic combinations used in tuberculosis therapy — combining drugs with different mechanisms specifically to prevent resistance emergence. Berberine delivers something approximating that effect in a single molecule.

The flip side is that the multi-target mechanism limits potency at any single target. Berberine's minimum inhibitory concentrations (MICs) are generally in the 25-200 µg/mL range for clinically relevant bacteria — 100-1000× less potent on a weight basis than a frontline antibiotic such as ciprofloxacin. The clinical effectiveness depends on achieving sufficient local concentration at the site of infection, which is easy in the gut lumen (where ingested berberine sees concentrations in the hundreds of µg/mL because absorption is so low) and on the skin or mucosal surface (where topical concentration can be even higher), but harder in systemic infection where plasma berberine after oral dosing typically peaks at 1-10 ng/mL.

Back to Table of Contents

The Antimicrobial Spectrum of Barberry / Berberine

Berberine has documented in vitro activity against an unusually broad range of pathogens. The following is a representative selection from the published minimum inhibitory concentration (MIC) literature, organized by target class:

Gram-positive bacteria. Staphylococcus aureus (including methicillin-resistant Staphylococcus aureus, MRSA), Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterococcus faecalis, Bacillus subtilis, Listeria monocytogenes. MICs typically 25-100 µg/mL. One exception is the gut germ Clostridioides difficile: a 2020 laboratory study of 12 strains (Wultańska 2020) measured berberine MICs of 256-1,024 mg/L (the same as µg/mL) and bactericidal concentrations of 256-16,384 mg/L, although berberine also boosted vancomycin against most strains in the dish. Gram-positive activity is generally stronger than gram-negative because the lipopolysaccharide outer membrane of gram-negatives slows berberine penetration.

Gram-negative bacteria. Escherichia coli (including enterotoxigenic ETEC and enteroinvasive EIEC strains), Vibrio cholerae, Salmonella enterica, Shigella dysenteriae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Helicobacter pylori, Yersinia enterocolitica. MICs typically 50-200 µg/mL. The intraluminal gut concentrations reached with oral barberry or berberine are described as high enough to reach these levels at the site of infection, but gut concentrations have not been measured against every germ, and some (such as C. difficile above) need far more.

Mycobacteria. Mycobacterium tuberculosis shows modest in vitro susceptibility (minimum inhibitory concentration around 200 µg/mL); the limited in vivo absorption makes berberine impractical as a tuberculosis (TB) therapy in modern practice, though it has been used adjunctively in resource-limited settings.

Fungi. Candida albicans (including some azole-resistant strains), Candida glabrata, Candida tropicalis, several dermatophytes including Trichophyton rubrum (athlete's foot) and Microsporum canis. Topical barberry preparations have demonstrated clinical utility in superficial fungal infection.

Protozoa. Giardia lamblia (extensive clinical data — see below), Entamoeba histolytica, Leishmania donovani, Trypanosoma brucei, Trichomonas vaginalis. The protozoal activity is particularly clinically useful because conventional protozoal therapy (metronidazole, tinidazole, paromomycin) often has gastrointestinal (GI) side effects, and berberine offers a relatively well-tolerated alternative.

Viruses. Modest in vitro activity against herpes simplex virus, influenza A, hepatitis B and C, and several other enveloped viruses. The clinical relevance is uncertain; berberine is not a primary antiviral agent.

Helicobacter pylori trials in people. Berberine has been tested alongside antibiotics against Helicobacter pylori, the stomach germ behind many ulcers. A meta-analysis of 13 randomized trials from China (Hu 2020) found that adding berberine to standard triple therapy raised the clearance rate (relative risk 1.22) and the ulcer-healing rate (relative risk 1.15), relieved symptoms more often (relative risk 1.11) and lowered side effects (relative risk 0.65) compared with triple therapy alone. A 2023 randomized trial of 300 patients in China (Chen 2023) compared 14 days of berberine 500 mg + amoxicillin + vonoprazan (a stomach-acid blocker), all twice daily, with two standard four-drug regimens: clearance was 81.4%, 86.5% and 78.4% per protocol (70%, 77% and 69% of everyone enrolled), not significantly different, and side effects were similar. All of these trials used berberine together with antibiotics, not berberine or barberry alone.

Back to Table of Contents

The 1985 Burma and 1987 Bangladesh Diarrhoea Trials

Two randomized hospital trials from the 1980s are the main human evidence for berberine in bacterial diarrhoea. They are often blended together into one trial, but they were separate studies with different results.

Khin-Maung-U 1985 (Burma, British Medical Journal). Four hundred adults with acute watery diarrhoea entered a randomised, placebo-controlled, double-blind trial with four arms:

• Berberine
• Tetracycline (an antibiotic)
• Tetracycline + berberine
• Placebo

Among the 185 patients with cholera, the two tetracycline groups had much less stool, shorter diarrhoea and needed less rehydration fluid. Berberine on its own did not produce an antisecretory effect (it did not reduce the fluid pouring into the gut). A factorial statistical analysis did find about one litre less diarrhoeal stool, and a 77% fall in stool cyclic AMP (the chemical messenger cholera toxin switches on), in the groups that received berberine. Fewer patients given tetracycline were still passing cholera germs after 24 hours than those given berberine alone. In the other 215 patients, whose diarrhoea was not cholera, neither tetracycline nor berberine did better than placebo.

Rabbani 1987 (Bangladesh, Journal of Infectious Diseases). This randomized controlled trial studied 165 adults with acute diarrhoea caused by enterotoxigenic E. coli (ETEC) or Vibrio cholerae:

• ETEC diarrhoea — after a single 400 mg oral dose of berberine sulfate, stool volumes were significantly lower than in the controls in each of the three 8-hour periods after treatment, and at 24 hours 42% of treated patients had stopped having diarrhoea, compared with 20% of controls.
• Cholera — with 400 mg, stool volume in the second 8-hour period was 2.22 litres versus 2.79 litres in controls.
• Berberine added to tetracycline — patients with cholera given 1,200 mg of berberine plus tetracycline did not pass significantly less stool than those given tetracycline alone.
• Side effects — none were noted from berberine.

The authors concluded that berberine sulfate is an effective and safe antisecretory drug for ETEC diarrhoea, whereas its activity against cholera is slight and not additive with tetracycline.

How berberine acts on the toxins. In a 1982 animal study (Sack and Froehlich), berberine cut the fluid response to the heat-labile toxins of V. cholerae and E. coli by about 70% in tied-off loops of rabbit intestine, and also markedly reduced the response to the E. coli heat-stable toxin in infant mice. It worked whether it was given before or after the toxin had bound to the gut wall, and whether it was given into the gut or by injection; it did not stop the toxin from switching on the enzyme adenylate cyclase, and it caused no visible damage to the gut lining. The authors wrote that the mechanism of action was not yet known.

What the two trials do and do not show.

1. A single 400 mg dose of berberine sulfate reduced stool output and sped recovery in ETEC diarrhoea (Rabbani 1987).
2. In cholera the effect was slight (Rabbani 1987) or absent as an antisecretory effect (Khin-Maung-U 1985); tetracycline was the treatment that clearly worked.
3. Adding berberine to tetracycline gave no additional reduction in cholera stool output (Rabbani 1987).
4. In watery diarrhoea that was not cholera, berberine did no better than placebo in the Burma trial (Khin-Maung-U 1985).
5. No side effects of berberine were noted at the doses tested (Rabbani 1987).

Both trials are small by modern standards, follow-up was short, and the comparator was tetracycline rather than the antibiotics used today (azithromycin or fluoroquinolones). Together they show a measurable effect of berberine in ETEC diarrhoea and at most a slight effect in cholera. This is the foundation of modern phytotherapeutic use of berberine in traveler's diarrhea and the rationale for the World Health Organization (WHO) traditional medicine listing.

Back to Table of Contents

Barberry vs Goldenseal — the NorA Efflux Pump Question

Barberry (Berberis vulgaris) and goldenseal (Hydrastis canadensis) both contain berberine as their primary antimicrobial alkaloid. From a pure-berberine standpoint, the two herbs should be roughly interchangeable, with barberry actually offering a higher berberine yield per gram of crude herb than goldenseal in some growing conditions. In practice, however, goldenseal has a reputation among herbalists as the stronger antimicrobial for certain uses, particularly skin and mucosal infections caused by gram-positive bacteria. Goldenseal also contains alkaloids that barberry lacks, such as hydrastine, a phthalideisoquinoline alkaloid present at 1.5-4% of dried goldenseal root by weight and a weaker antimicrobial than berberine. The laboratory research on "helper" compounds, however, does not point to hydrastine.

The key bacterial target is the NorA efflux pump — a multidrug resistance pump found in Staphylococcus aureus and several other gram-positive species. NorA actively expels berberine (among many other compounds) out of the bacterial cell, lowering the berberine concentration inside the germ and limiting its antimicrobial action.

• Barberry-family plants make their own pump blocker. Stermitz and colleagues (2000) found that several medicinal Berberis plants that produce berberine also make an inhibitor of the NorA pump, identified as 5'-methoxyhydnocarpin. On its own it had no germ-killing activity, but it strongly boosted berberine against S. aureus, completely blocked the pump's expulsion of berberine and made berberine build up inside the bacteria.
• Goldenseal's pump blockers are leaf flavonoids. Junio and colleagues (2011) found three synergists in goldenseal — the flavonoids sideroxylin, 8-desmethyl-sideroxylin and 6-desmethyl-sideroxylin — which boost berberine against S. aureus by blocking NorA and have no germ-killing activity of their own. They are more concentrated in goldenseal leaves, while berberine is more concentrated in the roots, so the authors suggested that a mix of root and leaf might give the strongest extract.

This is one of the clearest documented examples of plant synergy ("entourage effect") in herbal medicine, with a measured mechanism. All of it is laboratory work on bacteria in dishes; no trial in people has compared barberry and goldenseal preparations against each other.

How the two herbs compare in use:

• Acute bacterial diarrhea (cholera, ETEC, dysentery) — barberry and goldenseal are generally treated as roughly interchangeable. The berberine concentration in the gut lumen is high enough that NorA-mediated efflux is not thought to be the rate-limiting factor.
• Skin or topical mucosal staph infection — goldenseal has the stronger traditional reputation. The pump-blocking compounds behind the laboratory synergy are goldenseal's leaf flavonoids (not hydrastine) and, in barberry-family plants, 5'-methoxyhydnocarpin; how much of either ends up in a given root preparation varies.
• Systemic indications (where overall systemic exposure is the goal, not a particular pathogen) — barberry is far more sustainable and far cheaper than goldenseal (the latter is on the United Plant Savers At-Risk list due to historical overharvesting from wild populations).
• Traditional bitter and cholagogue uses — barberry is the classical European/Persian choice and is traditionally used in the same way as goldenseal at much lower cost.

For more on goldenseal specifically, including its hydrastine, canadine, and berberastine alkaloid profile, see our Goldenseal page.

Back to Table of Contents

Giardiasis and Other Protozoal Infection

Giardia lamblia (also called G. duodenalis or G. intestinalis) is a flagellated protozoan parasite that colonizes the proximal small intestine and causes chronic diarrhea, malabsorption, abdominal cramping, and the classic "rotten egg" sulfurous flatulence. Standard therapy is metronidazole (250 mg three times daily for 5-7 days) or tinidazole (single 2-gram dose), both of which are highly effective but commonly cause gastrointestinal side effects including a metallic taste, nausea, and disulfiram-like reactions with alcohol. Resistance is also a growing concern.

Berberine has substantial documented activity against Giardia in vitro and in clinical trials. A 1972 trial in Indian children by Choudhry and colleagues is described in secondary sources as having randomized 137 children with giardiasis to one of four treatments — metronidazole, furazolidone, berberine 5-10 mg/kg/day in three divided doses, or placebo. The metronidazole arm achieved approximately 95% cure rate, the furazolidone arm 90%, and the berberine arm 68% cure rate. (The PubMed record of this paper has no abstract, so these figures come from later descriptions of it.) Berberine was less effective than metronidazole but substantially better than placebo, and the side-effect profile was much milder than either of the comparator drugs. Subsequent smaller trials have replicated this general pattern: berberine is a second-line or adjunctive option for giardiasis, useful particularly when conventional therapy is contraindicated, has failed, or is poorly tolerated.

Other protozoal applications:

• Amebiasis (Entamoeba histolytica) — berberine has documented activity, used in traditional Asian medicine. Modern first-line is metronidazole + paromomycin; berberine is an adjunct or alternative when conventional therapy is contraindicated.
• Leishmaniasis (visceral and cutaneous) — berberine derivatives have been explored as leishmaniasis therapies, with some promising in vivo data but no widespread clinical adoption.
• Trichomoniasis — modest in vitro activity, no robust clinical evidence.
• Cryptosporidiosis — some in vitro activity reported; clinical evidence is sparse.

For more on parasite protocols generally, see our Parasites page.

Back to Table of Contents

Traveler's Diarrhea and Acute Gastroenteritis

Traveler's diarrhea affects 20-50% of international travelers to high-risk destinations and is most commonly caused by enterotoxigenic E. coli (ETEC), enteroaggregative E. coli (EAEC), Campylobacter jejuni, Salmonella enterica, Shigella, or norovirus. The conventional approach is oral rehydration plus, for moderate to severe symptoms, a fluoroquinolone (rapidly losing efficacy due to Campylobacter resistance) or azithromycin (current preferred frontline for Southeast Asia and the Indian subcontinent).

Berberine is used by some travellers and practitioners as a preventive or treatment option for traveler's diarrhea. The trial support is the Rabbani 1987 result in ETEC diarrhoea (ETEC is the most common cause), together with the laboratory spectrum above; no trial of berberine for prevention in travellers is cited on this page. Doses described in practitioner and supplement use:

• Prevention — 400 mg berberine HCl once or twice daily during travel in high-risk regions. Note: this is the standardized supplement, not barberry crude root; achieving the equivalent berberine dose from barberry root would require approximately 40-50 g daily of dried root, which is impractical.
• Acute treatment at symptom onset — 400-500 mg berberine HCl three to four times daily for 3-5 days, usually started at the first onset of loose stool. Often combined with oral rehydration salts.
• Barberry tincture for milder cases — 2-3 mL (40-60 drops) of 1:5 tincture every 2-4 hours during acute symptoms. Less potent than standardized berberine but more accessible in some settings and useful for the bitter / digestive effect alongside the antimicrobial action.

The advantages claimed for berberine over antibiotic prophylaxis are the absence of the resistance-pressure problem, a milder effect on the commensal microbiome (although the first review of human trials, below, found the changes were not uniformly favourable), and the side-effect profile. The disadvantage is somewhat lower efficacy than azithromycin or rifaximin for severe bacterial diarrhea, and the fact that berberine is poorly absorbed and cannot treat systemic infection — fever with bloody stools is a sign of invasive infection, which hospitals treat as urgent and treat with antibiotics.

Back to Table of Contents

Urinary Tract Infections

Acute uncomplicated urinary tract infection in women is most commonly caused by uropathogenic Escherichia coli (UPEC, approximately 80% of cases), with Staphylococcus saprophyticus, Klebsiella, and Proteus mirabilis rounding out the next 15-20%. The classical bladder-infection presentation responds to short-course antibiotics (nitrofurantoin, trimethoprim-sulfamethoxazole, or fosfomycin), but recurrent urinary tract infection (UTI) is increasingly common as antibiotic resistance grows and as the consequences of repeated antibiotic exposure on the vaginal and gut microbiome become better appreciated.

Berberine has two relevant mechanisms for urinary tract infection prevention and adjunctive treatment:

1. Anti-adhesion effect on FimH — berberine downregulates the type-I fimbriae and the FimH mannose-binding adhesin that UPEC uses to adhere to the bladder uroepithelium. Without adhesion, the bacteria are washed out with urine before they can colonize. This is mechanistically similar to the proanthocyanidin (PAC) action of cranberry but operates through a different molecular target.
2. Direct antibacterial action against UPEC — the spectrum and minimum inhibitory concentration data above. Urinary berberine concentration after oral dosing is meaningful (the absorbed fraction is largely excreted unchanged in urine), and topical concentration on the uroepithelium can be bactericidal.

Clinical evidence for berberine in urinary tract infection is more limited than for diarrheal disease. Practitioners describe combining berberine 500 mg twice daily with D-mannose 1-2 g twice daily to prevent recurrent urinary tract infection; no randomized trial of this combination, and no comparison with low-dose nitrofurantoin, was found when this page was checked. Berberine has not been tested as a replacement for antibiotics in acute symptomatic urinary tract infection, and a bladder infection that is not cleared can spread to the kidneys (pyelonephritis).

For more on urinary tract infection, see our Urinary Tract Infections page.

Back to Table of Contents

Skin, Eye, and Mucosal Infection

Topical berberine and barberry root preparations have a long history of use in skin infection, conjunctivitis, oral mucosal ulceration, and otitis externa. The advantage of topical use is that concentration at the site of infection can easily reach the bactericidal/fungicidal range without any concern about poor systemic absorption.

• Bacterial skin infections (impetigo, folliculitis, infected eczema) — topical 0.1-0.5% berberine cream or 1:5 barberry tincture diluted 1:5 with water for compress application. Goldenseal salves have a reputation for outperforming pure barberry preparations for staphylococcal skin infection; in the laboratory, goldenseal's NorA pump-blocking helpers are leaf flavonoids rather than hydrastine (see the goldenseal section above).
• Fungal skin infection (athlete's foot, ringworm) — topical 0.1-0.5% berberine has documented efficacy against Trichophyton and Microsporum dermatophytes. Often combined with tea tree oil (1-5%) for synergistic effect.
• Bacterial and viral conjunctivitis — sterile 0.2% berberine eye drops have a long history of use for conjunctivitis in traditional Chinese ophthalmology. Modern data is sparse but the topical safety profile is good. Berberine eye drops are commercially available in China as a non-prescription product.
• Oral mucosal ulceration (aphthous stomatitis, post-radiation mucositis) — berberine mouthwashes (50-200 mg berberine in 10 mL water, swished and spat 3-4×/day) have demonstrated benefit in trials of recurrent aphthous ulcers and chemotherapy/radiation-induced mucositis.
• Otitis externa — dilute berberine ear drops (0.1% in glycerin or in propylene glycol vehicle) have traditional use in chronic otitis externa, particularly when caused by Pseudomonas or Staphylococcus. Modern data is limited.

Back to Table of Contents

Effect on the Commensal Gut Microbiome

A common and reasonable concern about long-term berberine use is the effect on the commensal gut microbiome. Berberine is, after all, a broad-spectrum antibacterial with high intraluminal gut concentrations. Would chronic berberine use destroy the commensal microbiome the way long-term broad-spectrum antibiotics do?

The picture is more nuanced than a simple equivalence with antibiotic-induced dysbiosis would predict, and the animal and human results do not fully agree. Animal studies and some smaller studies have reported the following:

• Reduced abundance of pathobionts — berberine reduces relative abundance of opportunistic pathogens including pathogenic E. coli, Clostridium species (including C. difficile), and several other pro-inflammatory taxa.
• Increased abundance of short-chain-fatty-acid producers — counterintuitively, berberine appears to increase the abundance of beneficial short-chain fatty acid-producing taxa including Akkermansia muciniphila, Faecalibacterium prausnitzii, Roseburia, and Bifidobacterium. The proposed mechanism is partly direct (some of these taxa appear to be relatively resistant to berberine compared with pathobionts) and partly indirect via the removal of competitive pressure from pathogen overgrowth.
• Increased microbiome diversity — alpha-diversity metrics typically increase, not decrease, on chronic berberine therapy — the opposite of what happens with conventional antibiotics.
• Restored bile-acid metabolism — berberine appears to shift the secondary bile acid profile in a direction associated with improved insulin sensitivity and reduced hepatic steatosis.

The first systematic review of randomized trials in people (Candrea 2026) found a less tidy picture. It included seven trials, with 34 to 446 participants per treatment group, in type 2 diabetes, high blood fats, colorectal adenoma (bowel polyps), psychiatric illness and Parkinson's disease. Berberine changed the make-up of the gut bacteria in six of the seven. The most studied changes, mostly in people with type 2 diabetes, were a rise in gamma-Proteobacteria (the bacterial group that includes E. coli) and a fall in butyrate-producing bacteria — the opposite of the rise in short-chain fatty acid producers reported in animals. Fasting glucose, blood fats and inflammation markers improved at the same time, but the trials could not show that the bacterial changes caused those improvements. The authors wrote that the shifts were not uniformly favourable and that the findings should be treated as a starting point for further research.

Why berberine would spare some beneficial taxa in animals is not entirely understood. One hypothesis is that the short-chain fatty acid-producing commensals are intrinsically less susceptible to berberine because they rely less on the FtsZ-dependent cell-division machinery (some have alternative septum-formation mechanisms). Another is that berberine's anti-inflammatory effect on the host gut epithelium restores conditions favorable to commensal growth. Whatever the mechanism, the net effect for long-term berberine use is favorable in terms of microbiome composition, and this is a significant advantage over conventional antibiotic prophylaxis. In people, whether long-term berberine use leaves the microbiome better or worse off has not been settled.

For more on gut health generally, see our Gut Healing page.

Back to Table of Contents

Dosing and Practical Forms (Decoction, Tincture, Capsule)

Barberry root decoction. 1-2 teaspoons (2-4 g) of dried, crushed barberry root bark simmered in 250-300 mL water for 15-20 minutes, strained, and consumed 2-3× daily. The tea has a strong bitter taste that is part of the cholagogue / digestive effect. Approximate berberine delivery: 50-100 mg per cup. This is the classical preparation for digestive bitter and mild antimicrobial use.

Barberry tincture (1:5, 40-50% alcohol). 30-60 drops (2-4 mL) diluted in water, 2-3× daily before meals for digestive use; up to 4×/day for acute antimicrobial use. The alcohol vehicle enhances berberine extraction and improves shelf life. Tinctures are convenient and dose-titratable.

Barberry capsules (standardized). Commercial barberry capsules are typically standardized to 5-10% berberine and dosed at 400-500 mg of dried root extract, 2-3×/day. Approximate berberine delivery: 20-50 mg per capsule. This is far less berberine than the standardized berberine HCl supplements typically deliver (500 mg berberine per capsule).

Standardized berberine HCl supplements (extracted from Coptis or Phellodendron). The form used in the Yin 2008 metformin-comparison trial and most modern cardiometabolic protocols. Typically 500 mg three times daily with meals. Not "barberry" per se but the same active alkaloid.

Topical preparations. 0.1-0.5% berberine in cream, ointment, gel, or compress for skin infection. Eye drops at 0.2%, mouthwash at 50-200 mg per 10 mL water, ear drops at 0.1% in glycerin vehicle.

For acute use (e.g., traveler's diarrhea, acute giardiasis, acute bacterial gastroenteritis), the higher-dose standardized berberine HCl is more practical than the whole-herb barberry preparations because the dose required to achieve clinical effect is impractical to deliver as crude root. For chronic, lower-dose use (digestive bitter, mild antimicrobial maintenance, cholagogue), the whole-herb tincture or decoction is the traditional form and provides the additional benefit of the bitter cephalic-phase digestive effect.

Back to Table of Contents

Cautions and Drug Interactions

• Pregnancy and breastfeeding (contraindicated) — berberine crosses the placenta and is found in breast milk. It can displace bilirubin from albumin binding, increasing free bilirubin levels and risking kernicterus in newborns. Barberry preparations are also uterine stimulants in some animal models. For these reasons, herbal references list barberry and standardized berberine as not for use in pregnancy or breastfeeding.
• Infants (contraindicated) — same kernicterus / bilirubin-displacement concern, which is why berberine is listed as unsafe for infants.
• Cytochrome P450 3A4 (CYP3A4) inhibition (significant drug interaction) — berberine is a potent inhibitor of cytochrome P450 3A4, the enzyme responsible for metabolism of approximately half of all prescription drugs. Significant interactions are well-documented with cyclosporine (greatly increased cyclosporine levels), tacrolimus, several statins (atorvastatin, simvastatin, lovastatin), some calcium channel blockers, and many others. The risk is greatest for people taking several prescription drugs that are broken down by cytochrome P450 3A4, because each of them can build up in the blood.
• Hypoglycemia with diabetes medications — the AMP-activated protein kinase / glucose-lowering action of berberine adds to the effect of metformin, sulfonylureas, insulin, and other antidiabetics. When berberine is added to an existing diabetes regimen, blood sugar can fall lower than with the medicines alone, and the doses of conventional medications are often lowered as a result.
• Gastrointestinal tolerability — the most common adverse effect is constipation (for some patients) or diarrhea (for others) at higher doses. Splitting the dose, taking with food, or stepping down the dose typically resolves the symptom. Some patients report bitter or metallic taste, which is the cephalic-phase bitter effect and not a true adverse reaction.
• Anticoagulants — berberine may potentiate warfarin and other anticoagulants, so starting or stopping berberine can shift the international normalized ratio (INR), the blood-clotting test used to track warfarin.
• Hypotension — berberine has mild vasodilator effects and may augment antihypertensive drugs, adding to the blood-pressure fall in people taking several of them.

Back to Table of Contents

Key Research Papers

1. Khin-Maung-U, Myo-Khin, Nyunt-Nyunt-Wai, Aye-Kyaw, Tin-U (1985). Clinical trial of berberine in acute watery diarrhoea. British Medical Journal (Clinical Research Edition) 291(6509):1601-1605. — PubMed PMID: 3935203
2. Rabbani GH, Butler T, Knight J, Sanyal SC, Alam K (1987). Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and Vibrio cholerae. Journal of Infectious Diseases 155(5):979-984. — PubMed PMID: 3549923
3. Choudhry VP, Sabir M, Bhide VN (1972). Berberine in giardiasis. Indian Pediatrics 9(3):143-146. — the classical comparison of berberine, metronidazole, and furazolidone in pediatric giardiasis (no abstract on PubMed). PubMed PMID: 4555485
4. Cernakova M, Kostalova D (2002). Antimicrobial activity of berberine — a constituent of Mahonia aquifolium. Folia Microbiologica. — comprehensive MIC tabulation across pathogen classes. PubMed PMID: 12422513
5. Stermitz FR et al. (2000). Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5'-methoxyhydnocarpin, a multidrug pump inhibitor. PNAS. — the foundational NorA-pump synergy paper, showing that Berberis plants make their own NorA pump inhibitor. PubMed PMID: 10677479
6. Imanshahidi M, Hosseinzadeh H (2008). Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytotherapy Research. — PubMed PMID: 18618524
7. Sun D, Courtney HS, Beachey EH (1988). Berberine sulfate blocks adherence of Streptococcus pyogenes to epithelial cells, fibronectin, and hexadecane. Antimicrobial Agents and Chemotherapy 32(9):1370-1374. — foundational anti-adhesion mechanism paper. PubMed PMID: 3058020
8. Wultańska D, Piotrowski M, Pituch H (2020). The effect of berberine chloride and/or its combination with vancomycin on the growth, biofilm formation, and motility of Clostridioides difficile. European Journal of Clinical Microbiology & Infectious Diseases 39(7):1391-1399. — PubMed PMID: 32140903
9. Sack RB, Froehlich JL (1982). Berberine inhibits intestinal secretory response of Vibrio cholerae and Escherichia coli enterotoxins. Infection and Immunity 35(2):471-475. — the antitoxin animal study (mechanism not known). PubMed PMID: 7035365
10. Domadia PN, Bhunia A, Sivaraman J, Swarup S, Dasgupta D (2008). Berberine targets assembly of Escherichia coli cell division protein FtsZ. Biochemistry 47(10):3225-3234. — mechanism paper for FtsZ inhibition. PubMed PMID: 18275156
11. Liu CS, Zheng YR, Zhang YF, Long XY (2016). Research progress on berberine with a special focus on its oral bioavailability. Fitoterapia 109:274-282. — covers the absorption / efflux pump issues. PubMed PMID: 26851175
12. Junio HA, Sy-Cordero AA, Ettefagh KA, Burns JT, Micko KT, Graf TN, Richter SJ, Cannon RE, Oberlies NH, Cech NB (2011). Synergy-directed fractionation of botanical medicines: a case study with goldenseal (Hydrastis canadensis). Journal of Natural Products 74(7):1621-1629. — goldenseal's NorA-blocking leaf flavonoids. PubMed PMID: 21661731
13. Candrea AR, Gavrilaș LI, Frumuzachi O, Mocan A, Babotă M, Crișan G (2026). The Integrative Role of Berberine in Gut Microbiota Modulation and Cardiometabolic Outcomes: A Systematic Review of Randomised Clinical Trials. Nutrients 18(12):1858. — the first systematic review of human trials on berberine and the gut microbiome. PubMed PMID: 42356246
14. Hu Q, Peng Z, Li L, Zou X, Xu L, Gong J, Yi P (2020). The Efficacy of Berberine-Containing Quadruple Therapy on Helicobacter Pylori Eradication in China: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Frontiers in Pharmacology 10:1694. — PubMed PMID: 32116685
15. Chen S, Shen W, Liu Y, Dong Q, Shi Y (2023). Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial. Chinese Medical Journal 136(14):1690-1698. — PubMed PMID: 37469024

PubMed Topic Searches

1. PubMed: Berberine antimicrobial mechanism
2. PubMed: Berberine cholera / ETEC
3. PubMed: Berberine and Giardia
4. PubMed: Berberine and MRSA
5. PubMed: Berberine FtsZ mechanism
6. PubMed: Berberine gut microbiome

Back to Table of Contents

Connections

• All Herbs
• Barberry Overview
• Barberry Benefits Hub
• Barberry for Blood Sugar
• Barberry for Liver Health
• Barberry as a Digestive Aid
• Berberine (Standardized Supplement)
• Berberine Benefits Deep Dive
• Goldenseal (Hydrastine + NorA Synergy)
• Oregano
• Parasites
• Gut Healing
• Escherichia Coli
• Staphylococcus Aureus
• Klebsiella Pneumoniae
• Urinary Tract Infections
• Irritable Bowel Syndrome
• History

Back to Table of Contents

×

Featured Videos